Patents by Inventor Frederick Cohen

Frederick Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition
    Patent number: 12653809
    Abstract: Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells invivo, in vitro, or ex vivo.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: June 16, 2026
    Assignee: Nurix Therapeutics, Inc.
    Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Morgan Lawrenz, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
    Patent number: 12485144
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Grant
    Filed: February 15, 2024
    Date of Patent: December 2, 2025
    Assignee: NURIX THERAPEUTICS, INC.
    Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF
    Publication number: 20250136590
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Application
    Filed: October 25, 2024
    Publication date: May 1, 2025
    Inventors: Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING
  • Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
    Patent number: 12234230
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: February 25, 2025
    Assignee: NURIX THERAPEUTICS, INC.
    Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF
    Publication number: 20240409555
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Application
    Filed: June 18, 2024
    Publication date: December 12, 2024
    Inventors: Arthur T. SANDS, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
    Publication number: 20240400587
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
    Type: Application
    Filed: August 7, 2024
    Publication date: December 5, 2024
    Inventors: John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak
  • Modular synthesis of aminoglycosides
    Patent number: 12129274
    Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: October 29, 2024
    Assignee: Revagenix, Inc.
    Inventors: Andrew Antony Calabrese, Timothy Robert Kane, Darin Hildebrandt, Michael Lopez, Nikolai Evdokimov, Frederick Cohen, Malken Bayrakdarian, Sanijia Xu, Samuel Desjardins, Olivier Soueidan
  • Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
    Patent number: 12091426
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: September 17, 2024
    Assignees: Nurix Therapeutics, Inc., Gilead Sciences, Inc.
    Inventors: John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak
  • 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF
    Publication number: 20240293458
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Application
    Filed: February 15, 2024
    Publication date: September 5, 2024
    Inventors: Arthur T. SANDS, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
    Patent number: 12049471
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: July 30, 2024
    Assignee: NURIX THERAPEUTICS, INC.
    Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • Inhibitors of IAP
    Patent number: 11963994
    Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: April 23, 2024
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
  • 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
    Patent number: 11951133
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: April 9, 2024
    Assignee: NURIX THERAPEUTICS, INC.
    Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
    Publication number: 20240018162
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
    Type: Application
    Filed: November 9, 2022
    Publication date: January 18, 2024
    Inventors: John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak
  • CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF
    Publication number: 20230212186
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Application
    Filed: December 19, 2022
    Publication date: July 6, 2023
    Inventors: Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING
  • Modular synthesis of aminoglycosides
    Patent number: 11673907
    Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 13, 2023
    Assignee: Revagenix, Inc.
    Inventors: Andrew Calabrese, Timothy Robert Kane, Darin Hildebrandt, Michael Lopez, Nikolai Evdokimov, Frederick Cohen, Malken Bayrakdarian, Sanjia Xu, Samuel Desjardins, Olivier Soueidan
  • MODULAR SYNTHESIS OF AMINOGLYCOSIDES
    Publication number: 20230167148
    Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.
    Type: Application
    Filed: December 21, 2022
    Publication date: June 1, 2023
    Inventors: Andrew Antony Calabrese, Timothy Robert Kane, Darin Hildebrandt, Michael Lopez, Nikolai Evdokimov, Frederick Cohen, Malken Bayrakdarian, Sanijia Xu, Samuel Desjardins, Olivier Soueidan
  • SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF
    Publication number: 20230150991
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Application
    Filed: June 29, 2022
    Publication date: May 18, 2023
    Inventors: Arthur T. SANDS, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • MODULAR SYNTHESIS OF AMINOGLYCOSIDES
    Publication number: 20220411456
    Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.
    Type: Application
    Filed: August 24, 2018
    Publication date: December 29, 2022
    Applicant: Revagenix, Inc.
    Inventors: Andrew CALABRESE, Timothy Robort KANE, Darin HILDEBRANDT, Michael LOPEZ, Nikolai EVDOKIMOV, Frederick COHEN, Malken BAYRAKDARIAN, Sanijia XU, Samuel DESJARDINS, Olivier SOUEIDAN
  • Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
    Patent number: 11530229
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: December 20, 2022
    Assignee: NURIX THERAPEUTICS, INC.
    Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION
    Publication number: 20220387395
    Abstract: Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.
    Type: Application
    Filed: July 27, 2020
    Publication date: December 8, 2022
    Inventors: Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Morgan LAWRENZ, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING